Health & WellnessTech
Tactogen
Developing new MDMA-like medicines for effective prescription mental wellness.
Palo Alto,
CA
Investment type:
Equity
(SAFE)
Target raise:
$50,000
- $5,000,000
Minimum investment:
$100
$100
End date:
Feb 11, 2023
Feb 11, 2023
ended
Share
Highlights
- Tactogen is a public benefit corporation making entactogen (MDMA-like) molecules.
- CEO leverages 30+ years of experience in psychedelic preclinical and clinical research.
- Many lead compounds ready for safety and toxicity studies. $2-4 million will complete that process.
- Raised $6.3 million over 2.5 years from well known investors.
Our Story
Tactogen is a drug discovery and development organization making transformative medicines. Our focus for our first novel molecules is MDMA-like effects.
Our Ambition
We aim to be completing Phase 3 clinical trials for our first novel molecule and seeking FDA approval.